Author

Anatol Oleksijew

AbbVie (United States)

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 1 Research Focus:cell type annotation· 1 Research Focus:clustering· 1 Approach:deep learning· 1 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1 Organism:human· 1 Assay:scRNA-seq· 1

Frequent Co-Authors

Alexandre WojcinskiiD· 1 shared Anna M. JermakowicziD· 1 shared Danielle M. BurgenskeiD· 1 shared Edward B. ReillyiD· 1 shared Grace Baker· 1 shared Gregory SteiniD· 1 shared Jann Nagina SarkariaiD· 1 shared L.G. ZhangiD· 1 shared

Activity by Year

2026-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Alexandre WojcinskiORCID

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

Drug and single-cell gene expression integration identifies sensitive and resistant glioblastoma cell populations

Robert K. Suter, Anna M. Jermakowicz, Rithvik Veeramachaneni, Matthew D’Antuono, L.G. Zhang, Rishika Chowdary, Simon Kaeppeli, Madison Sharp, Pravallika Palwai, Vasileios Stathias, Grace Baker, Luz Clarita Ruiz, Winston M. Walters, Maria L. Cepero, Danielle M. Burgenske, , Nagi G. Ayad

The paper integrates single-cell RNA sequencing data with drug response signatures to identify drug-sensitive and resistant glioblastoma cell states and predict synergistic drug combinations.

Nature Communications · Jan 7, 2026Peer-reviewedCancer Biology